These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8204026)

  • 1. [The pharmacokinetics of hypolipemic agents. 10. The dehalogenation of the hypolipemic agent ciprofibrate].
    Oelschläger H; Hellwich KH; Rothley D
    Arch Pharm (Weinheim); 1994 Apr; 327(4):261-5. PubMed ID: 8204026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Conjugation reactions of ciprofibrate with human and laboratory animals].
    Oelschläger H; Müller D; Hellwich KH; Ueberall S; Seeling A; Machts H; Hofmann B; Glöckner R
    Arzneimittelforschung; 2003; 53(4):247-53. PubMed ID: 12785120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
    Oelschläger H; Rothley D; Schmidt W
    Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
    [No Abstract]   [Full Text] [Related]  

  • 5. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
    Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
    Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
    Masnatta LD; Cuniberti LA; Rey RH; Werba JP
    J Chromatogr B Biomed Appl; 1996 Dec; 687(2):437-42. PubMed ID: 9017468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ciprofibrate: erythrocyte partition coefficient and binding to serum protein].
    Czejka M
    Arch Pharm (Weinheim); 1991 May; 324(5):287-9. PubMed ID: 1888266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days.
    Desager JP; Horsmans Y; Vandenplas C; Harvengt C
    Atherosclerosis; 1996 Jul; 124 Suppl():S65-73. PubMed ID: 8831918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The enantiomeric resolution of ciprofibrate and related compounds by HPLC using chiral stationary phases.
    Anderson NH; Johnston D; Vojvodic PR
    J Pharm Biomed Anal; 1992 Jul; 10(7):501-5. PubMed ID: 1420475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of ciprofibrate in human plasma by high-performance liquid chromatography.
    Park GB; Biddlecome CE; Koblantz C; Edelson J
    J Chromatogr; 1982 Feb; 227(2):534-9. PubMed ID: 7061664
    [No Abstract]   [Full Text] [Related]  

  • 12. Achiral and chiral determination of ciprofibrate and its glucuronide in human urine by capillary electrophoresis.
    Hüttemann H; Blaschke G
    J Chromatogr B Biomed Sci Appl; 1999 Jun; 729(1-2):33-41. PubMed ID: 10410925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
    Lupp A; Karge E; Deufel T; Oelschlägers H; Fleck C
    Arzneimittelforschung; 2008; 58(5):225-41. PubMed ID: 18589557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciprofibrate and lipid profile.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1994 Oct; 344(8927):955. PubMed ID: 7934365
    [No Abstract]   [Full Text] [Related]  

  • 15. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M; Fedelesova V; Mongiellova V; Cibulova L; Huttova D; Polak F; Krivosikova Z
    Bratisl Lek Listy; 1999 Aug; 100(8):449-53. PubMed ID: 10645034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute rhabdomyolysis during treatment with ciprofibrate].
    Delangre T; Vernier L; Moore N; Mihout B
    Presse Med; 1990 Nov; 19(39):1811-2. PubMed ID: 2148009
    [No Abstract]   [Full Text] [Related]  

  • 17. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
    Harvengt C
    Acta Clin Belg; 1991; 46(2):117-9. PubMed ID: 1649529
    [No Abstract]   [Full Text] [Related]  

  • 18. [Ciprofibrate-induced acute cholestatic hepatitis].
    Pflumio F; Andrès E; Ubrich M; Geisler F; Imbs JL; Di Liberatore M
    Ann Endocrinol (Paris); 2003 Jun; 64(3):232-3. PubMed ID: 12910067
    [No Abstract]   [Full Text] [Related]  

  • 19. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO; Hjelm CJ; Canepo-Anson R
    Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract]   [Full Text] [Related]  

  • 20. [The pharmacokinetics of antilipemic agents. 8. Unequivocal characterization of ciprofibrate-O-beta-d-glucuronide].
    Oelschläger H; Kohl C; Armstrong DW; Rothley D
    Arch Pharm (Weinheim); 1991 Aug; 324(8):505-8. PubMed ID: 1781732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.